Light on the Horizont: Biologicals in Behçet uveitis

Acta Ophthalmologica

Volumn 91, Issue 4, 2013, Pages 297-306

  Hazirolan, Dicle ^a   Stübiger, Nicole ^b   Pleyer, Uwe ^b  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Beh et's disease; biologicals; infliximab; interferon; tumour necrosis factor alpha antagonist; Uveitis

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ALPHA2A INTERFERON; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; GAMMA INTERFERON; GOLIMUMAB; INFLIXIMAB; PREDNISOLONE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR;

ALOPECIA; ANTIBODY PRODUCTION; ATOPIC DERMATITIS; BEHCET DISEASE; BLINDNESS; CONGESTIVE HEART FAILURE; CORONARY ARTERY THROMBOSIS; CYTOKINE PRODUCTION; DEPRESSION; DERMATITIS; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; ERYTHEMA; FATIGUE; FIBROMYALGIA; FLU LIKE SYNDROME; FLUSHING; HAIR LOSS; HUMAN; HYPERTENSION; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE ULCER; LEUKOPENIA; LOW DRUG DOSE; LUNG EMBOLISM; LUPUS LIKE SYNDROME; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; MYALGIA; OPTIC NEURITIS; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; RELAPSE; REMISSION; RETINOPATHY; REVIEW; SARCOIDOSIS; SEIZURE; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; THROMBOCYTOPENIA; THYROIDITIS; TREATMENT DURATION; TUBERCULOSIS; UVEITIS; WEIGHT REDUCTION;

BEHCET SYNDROME; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; UVEITIS;

EID: 84878466078     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2011.02348.x     Document Type: Review

References (91)

1. Abu El-Asrar AM, Abboud EB, Aldibhi H, &, Al-Arfaj A, (2005): Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol 26: 83-92.
2. Al-Muammar AM, Al-Mudhaiyan TM, Al Otaibi M, Abdo A, &, Abu El-Asrar AM, (2010): Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection. Int Ophthalmol 30: 611-613.
3. Alpsoy E, Durusoy C, Yilmaz E, et al., (2002): Interferon alpha-2a in the treatment of Behcet disease: a randomized, placebo-controlled and double blind study. Arch Dermatol 138: 467-471.
4. Arida A, Fragiadaki K, Giavri E, &, Sfikakis PP, (2011): Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41: 61-70.
5. Baccala R, Hoebe K, Kono DH, Beutler B&, &, Theofilopoulos AN, (2007): TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 13: 543-551.
6. Bazzoni F, &, Beutler B, (1996): The tumor necrosis factor ligand and receptor families. N Engl J Med 334: 1717-1724.
7. Bodaghi B, Gendron G, Wechsler B, et al., (2007): Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 91: 335-339.
8. Chang C, &, Gershwin ME, (2011): Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf 34: 357-374.
9. Deuter CME, Kötter I, Wallace GR, Murray PI, Stübiger N, &, Zierhut M, (2008): Behçet's disease: ocular effects and treatment. Prog Retin Eye Res 27: 111-136.
10. Deuter CM, Zierhut M, Möhle A, Vonthein R, Stübiger N, &, Kötter I, (2010): Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behcet's disease. Arthritis Rheum 62: 2796-2805.
11. Doty JD, Mazur JE, &, Judson MA, (2005): Treatment of sarcoidosis with infliximab. Chest 127: 1064-1071.
12. Elezoglou A, Sfikakis PP, Vaiopoulos G, et al., (2003): Serum levels of soluble TNF receptor-II (p75), circulating γδ T-cells, and Adamantiades-Behcet's disease activity. Adv Clin Exp Biol 528: 261-265.
13. Elezoglou A, Kafasi N, Kaklamanis PH, et al., (2007): Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease. Clin Exp Rheumatol 25: S65-S69.
14. Ellerin T, Rubin RH, Weinblatt ME, et al., (2003): Infections and anti-tumor necrosis factor a therapy. Arthritis Rheum 48: 3013-3021.
15. Evereklioglu C, (2005): Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol 50: 297-350.
16. Fattovich G, Betterle C, Brollo L, et al., (1991): Autoantibodies during alpha-interferon therapy for chronic hepatitis B. J Med Virol 34: 132-135.
17. Feldmann M, &, Maini RN, (2001): Anti-TNF-a therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19: 163-196.
18. Foroozan R, Buono LM, Sergott RC, &, Savino PJ, (2002): Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol 120: 985-987.
19. Galor A, Perez VL, Hammel JP, &, Lowder CY, (2006): Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 113: 2137-2323.
20. Geri G, Terrier B, Rosenzwajg M, et al., (2011): Critical role of IL-21 in modulating T(H)17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol 128: 655-664.
21. Giardina A, Ferrante A, Ciccia F, et al., (2011): One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behcet's disease refractory to standard immunosuppressive drugs. Rheumatol Int 31: 33-37.
22. Goossens PH, Verburg RJ, &, Breedveld FC, (2001): Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis 60: 637.
23. Gueudry J, Wechsler B, Terrada C, et al., (2008): Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol 146: 837-844.
24. Gul A, (2001): Behcet's disease: an update on the pathogenesis. Clin Exp Rheumatol 19 (Suppl 24): S6-S12.
25. Hamuryudan V, Moral F, Yurdakul S, et al., (1994): Systemic interferon alpha 2b treatment in Behçet's syndrome. J Rheumatol 21: 1098-1100.
26. Hamuryudan V, Ozyazgan Y, Fresko Y, et al., (2002): Interferon alfa combined with azathioprine for the uveitis of Behcet's disease: an open study. Isr Med Assoc J 4: 928-930.
27. Haugeberg G, Velken M, &, Johnsen V, (2004): Successful treatment of genital ulcers with infliximab in Behcet's disease. Ann Rheum Dis 63: 744-745.
28. Heiberg MS, Nordvag BY, Mikkelsen K, et al., (2005): The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 52: 2506-2512.
29. Hyrich KL, Silman AJ, Watson KD, &, Symmons DPM, (2004): Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 63: 1538-1543.
30. Ito T, Sonoda KH, Hijioka K, Fujimoto T, &, Ishibashi T, (2010): Acquired resistance to infliximab against uveitis due to Behcet's disease after one year of administration. Jpn J Ophthalmol 54: 499-516.
31. Jabs DA, Rosenbaum JT, Foster CS, et al., (2000): Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130: 492-513.
32. Kaçmaz RO, Kempen JH, Newcomb J, et al., (2008): Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Group. Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 146: 828-836.
33. Kapsimali VD, Kanakis MA, Vaiopoulos GA, &, Kaklamanis PG, (2010): Etiopathogenesis of Behçet's disease with emphasis on the role of immunological aberrations. Clin Rheumatol 29: 1211-1216.
34. Katsiari CG, Theodossiadis PG, Kaklamanis P, Markomichelakis N, &, Sfikakis PP, (2003): Successful long-term treatment of refractory Adamantiades-Behçet's disease with Infliximab. Adv Clin Exp Biol 528: 551-555.
35. Kawano T, Shigehira M, Uto H, et al., (1996): Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 91: 309-313.
36. Keane J, Gershon S, Wise RP, et al., (1999): Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Med 345: 1098-1104.
37. Kempen JH, Daniel E, Gangaputra S, et al., (2008): Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol 15: 47-55.
38. Keystone EC, (2005): Safety of biologic therapies. An update. J Rheumatol 32: S8-S12.
39. Kim TW, Chung H, &, Yu HG, (2011): Chemokine expression of intraocular lymphocytes in patients with Behçet uveitis. Ophthalmic Res 45: 5-14.
40. Kitaichi N, Miyazaki A, Iwata D, et al., (2007): Ocular features of Behcet's disease: an international collaborative study. Br J Ophthalmol 91: 1579-1582.
41. Kötter I, Durk H, Saal J, et al., (1996): Therapy of Behçet's disease. Ger J Ophthalmol 5: 92-97.
42. Kötter I, Eckstein AK, Stubiger N, &, Zierhut M, (1998): Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 82: 488-494.
43. Kötter I, Zierhut M, Eckstein AK, et al., (2003): Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87: 423-431.
44. Kötter I, Günaydin I, Zierhut M, &, Stübiger N, (2004): The use of interferon alpha in Behçet disease: review of the literature. Semin Arthritis Rheum 33: 320-335.
45. Kötter I, Deuter C, Stübiger N, &, Zierhut M, (2005a): Interferon-a (IFN-a) application versus tumor necrosis factor-α antagonism for ocular Behcet's disease: focusing more on IFN. J Rheumatol 32: 1633, author reply 1634.
46. Kötter I, Koch S, Vonthein R, et al., (2005b): Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behcet's disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature. Clin Exp Rheumatol 23 (4 Suppl 38): S20-S26.
47. Krause L, Altenburg A, Pleyer U, et al., (2008): Longterm visual prognosis of patients with ocular Adamantiades-Behcet's disease treated with interferon-alpha-2a. J Rheumatol 35: 896-903.
48. Lee YB, Lee JI, Park HJ, Cho BK, &, Oh ST, (2011): Interferon-alpha Induced sarcoidosis with cutaneous involvement along the lines of venous drainage. Ann Dermatol 23: 239-241.
49. Lim LL, Fraunfelder FW, &, Rosenbaum JT, (2007): Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 56: 3248-3252.
50. Maini RN, Breedveld FC, Kalden JR, et al., (1998): Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552-1563.
51. Maini R, St. Clair WE, Breedveld F, et al., (1999): Infliximab (chimeric anti-tumour necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 354: 1932-1939.
52. Mohan N, Edwards ET, Cupps TR, et al., (2001): Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44: 2862-2869.
53. Niccoli L, Nannini C, Benucci M, et al., (2007): Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology 46: 1161-1164.
54. Ohno S, Nakamura S, Hori S, et al., (2004): Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 31: 1362-1368.
55. Okada AA, (2000): Drug therapy in Behcet's disease. Ocul Immunol Inflamm 8: 85-91.
56. Onal S, Kazokoglu H, Koc A, et al., (2011): Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol 129: 288-294.
57. Petitpain N, Gambier N, Wahl D, et al., (2009): Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006. Biomed Mater Eng 19: 355-364.
58. Plskova J, Greiner K, Muckersie E, et al., (2006): Interferon-alpha: a key factor in autoimmune disease? Invest Ophthalmol Vis Sci 47: 3946-3950.
59. Plskova J, Greiner K, &, Forrester JV, (2007): Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 144: 55-61.
60. Preziati D, La Rosa L, Covini G, et al., (1995): Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Ophthalmol 132: 587-593.
61. Quinn MA, Conaghan PG, O'Connor PJ, et al., (2005): Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52: 27-35.
62. Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, &, Khamashta MA, (2010): BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 9: 188-193.
63. Rhen T, &, Cidlowski JA, (2005): Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 353: 1711-1723.
64. Robertson LP, &, Hickling P, (2001): Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab. Rheumatology (Oxford) 40: 473-474.
65. Robinson WH, Genovese MC, &, Moreland LW, (2001): Demyelinating and neurologic events reported in association with TNF-a antagonism: by what mechanisms could TNF-a antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44: 1977-1983.
66. Sands BE, Anderson FH, Bernstein CN, et al., (2003): Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350: 876-885.
67. Sarwar H, McGrath H Jr, &, Espinoza LR, (2005): Successful treatment of long-standing neuro-Behçet's disease with infliximab. J Rheumatol 32: 181-183.
68. Sfikakis PP, &, Kollias G, (2003): TNF biology in experimental and clinical arthritis. Curr Opin Rheumatol 15: 380-386.
69. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, &, Markomichelakis NN, (2001): Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 358: 295-296.
70. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al., (2004): Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med 140: 404-406.
71. Sfikakis PP, Markomichelakis N, Alpsoy E, et al., (2007): Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology (Oxford) 46: 736-741.
72. Sobaci G, Erdem U, Durukan AH, et al., (2010): Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments. Ophthalmology 117: 1430-1435.
73. Suhler EB, Smith JR, Wertheim MS, et al., (2005): A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123: 903-912.
74. Tabbara KF, &, Al-Hemidan AI, (2008): Infliximab Effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol 146: 845-850.
75. Tamesis RR, Rodriguez A, Christen WG, et al., (1996): Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Ophthalmology 103: 768-775.
76. Tanaka T, Suzuki J, Yamakawa N, &, Usui M, (2000): Steroid sensitivity and postoperative course of seven patients with Behçet's disease. Ophthalmic Res 32: 41-43.
77. Theofilopoulos AN, Baccala R, Beutler B, &, Kono DH, (2005): Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23: 307-336.
78. Treusch M, Vonthein R, Baur M, et al., (2004): Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease. Rheumatology (Oxford) 43: 1275-1282.
79. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al., (2005): Efficacy of Infliximab in the treatment of uveitis that is refractory to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease. An open-label trial. Arthritis Rheum 52: 2478-2484.
80. Tugal-Tutkun I, Guney-Tefekli E, &, Urgancioglu M, (2006): Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol 244: 1692-1695.
81. Turan B, Gallati H, Erdi H, et al., (1997): Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease soluble TNFR-75 as a biologic marker of disease activity. J Rheumatol 24: 128-132.
82. Van der Heijde D, Dijkmans B, Geusens P, et al., (2005): Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52: 582-591.
83. Wandl UB, Nagel-Hiemke M, May D, et al., (1992): Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 65: 70-74.
84. Wechsler B, Sable-Fourtassou R, Bodaghi B, et al., (2004): Infliximab in refractory uveitis due to Behcet's disease. Clin Exp Rheumatol 22: S14-S16.
85. Whitcup SM, Salvo EC Jr, &, Nussenblatt RB, (1994): Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease. Am J Ophthalmol 118: 39-45.
86. Yamada Y, Sugita S, Tanaka H, et al., (2010): Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol 94: 284-288.
87. Yamada Y, Sugita S, Tanaka H, et al., (2011): Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment. Br J Ophthalmol 95: 205-208.
88. Yang DS, Taylor SR, &, Lightman SL, (2008): Interferon-alpha in the management of patients with Behcet's disease. Br J Hosp Med (Lond) 69: 575-579.
89. Yang DS, Galatowicz G, Calder VL, &, Lightman S, (2009): Upregulation of Foxp3 expression by recombinant interferon-alpha therapy in Behcet's disease. ARVO Meeting abstracts April 11 50: 1535.
90. Yazici H, Pazarli H, Barnes CG, et al., (1990): A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 322: 281-285.
91. Zaghetto JM, Yamamoto MM, Souza MB, et al., (2010): Chlorambucil and cyclosporine A in Brazilian patients with Behçet's disease uveitis: a retrospective study. Arq Bras Oftalmol 73: 40-46.